Value-Based Pricing or Fair Pricing—Which Approach Delivers Universal Health Coverage?

Published Nov 12, 2018
Barcelona, Spain—12 November 2018—ISPOR, the professional society for health economics and outcomes research, held a session this afternoon at ISPOR Europe 2018, “Health Technology Assessment Value-Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Health Coverage?” [IP8]. In this session, the speakers discussed whether value-based pricing or fair pricing is the right basis for decisions about which drugs to include in universal health coverage benefit packages for middle- and low-income countries. Speakers for this session included:
  • Moderator: Adrian Towse, MA, MPhil, Office of Health Economics, London, England, UK
  • Kalipso Chalkidou, MD, PhD, Center for Global Development, London, England, UK
  • Sarah Garner, PhD, World Health Organization, Geneva, Switzerland
The World Health Organization (WHO) has made the case that essential, life-saving medicines should not be evaluated by value-based pricing alone. WHO has stated that in addition to looking at differential pricing, cost effectiveness, and local thresholds, “fair pricing,” in which affordability and actual production and research costs are considerations, should be included in assessments. Dr Chalkidou supported the use of health technology assessment as an integral part of middle- and low-income country moves toward universal health coverage. In contrast, Dr Garner argued for the fair pricing approach that WHO has advocated and addressed issues including affordability, the need for effective procurement arrangements, and for transparency of R&D and production costs. ISPOR is recognized globally as the leading professional society in HEOR and its role in improving healthcare decisions. ISPOR Europe 2018 is the leading HEOR conference in Europe and draws more than 5000 healthcare stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, and patient engagement organizations. Additional information on ISPOR Europe 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBarcelona.

###

ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×